<DOC>
	<DOCNO>NCT00002941</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat child recurrent refractory Hodgkin 's lymphoma non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Children With Recurrent Refractory Hodgkin 's Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Estimate failure-free survival rate cohort relapse Hodgkin 's lymphoma non-Hodgkin 's lymphoma patient retrieval therapy include peripheral blood stem cell transplantation ( PBSCT ) patient achieve complete remission partial remission . - Estimate post complete/partial remission failure-free survival rate patient . - Characterize time recovery normal bone marrow function transplantation patient . OUTLINE : Patients receive 2 course reinduction chemotherapy follow bone marrow biopsy aspirate prior peripheral blood stem cell ( PBSC ) harvest . If marrow involvement still present harvest , 2 additional course induction chemotherapy give . The PBSC transplantation preparative regimen begin within 2 week complete reinduction therapy course , consist follow : - Carmustine IV 3 hour day -8 , -7 , -6 - Etoposide continuous IV day -8 , -7 , -6 - Cyclophosphamide IV 1 hour daily day -5 , -4 , -3 , -2 - Mesna 15 min infusion dose cyclophosphamide 3 , 6 , 9 , 12 hour initiation cyclophosphamide dose Methylprednisolone IV give protect lung toxic effect carmustine . PROJECTED ACCRUAL : A total 30 patient accrue subgroup .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma first relapse refractory primary induction therapy Histologically confirm Hodgkin 's lymphoma first relapse chemotherapy one nodal region involve relapse refractory primary induction therapy ( i.e. , fail achieve remission conclusion standard induction chemotherapy ) No prior radiotherapy low stage nodal disease No great 4 course standard chemotherapy low stage nodal disease CSF bone marrow involvement time study entry allow PATIENT CHARACTERISTICS : Age : 1 21 ( initial diagnosis ) Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : SGOT SGPT less 2.5 time normal Bilirubin great 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL Glomerular filtration rate great 60 mL/min measure radionuclide scan 24 hour urine collection creatinine clearance Cardiovascular : Shortening fraction least 28 % echocardiogram Ejection fraction least 40 % radionuclide angiogram echocardiogram Pulmonary : Total lung capacity ( TLC ) least 50 % OR Vital capacity ( VC ) least 65 % normal DLCO least 55 % normal For child uncooperative pulmonary function testing , dyspnea rest mild exercise , pulse oximetry least 95 % Other : HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
</DOC>